Skip to main content
TipRanks
Go Ultimate75% OFF

Ypsomed Holding AG (YPSN) Q2 2027 Earnings Report

6 Followers

CH:YPSN Q2 2027 EPS Results

Actual EPS
CHF 6.50
Consensus EPS
CHF 5.23
Beat/Miss
Beat by +CHF 1.27
One Year Ago EPS
CHF 10.19

CH:YPSN Q2 2027 Revenue Results

Actual Revenue
CHF 317.57M
Expected Revenue
CHF 314.14M
Beat/Miss
Beat by +CHF 3.43M
YoY Revenue Growth
-12.44%

Earnings Announcement Details

Quarter
Q2 2027
Date
11/11/2026
Time
Before Open
Conference Call
Wednesday, November 11, 2026
CH:YPSN Upcoming Earnings

Ypsomed Holding AG's next earnings date is estimated for May 26, 2027, based on past reporting schedules.

Q2 2027 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q2 2027 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2027 Earnings Call Summary

Q2 2027
Earnings Call Date:Nov 11, 2026|% Change Since:11.66%|
Earnings Call Sentiment|Positive

The call was strongly positive overall. Ypsomed reported robust first-half growth, record revenue and EBIT, significant new customer and project wins, strong autoinjector momentum, and raised full-year guidance. The company also confirmed its midterm targets and described substantial innovation and capacity expansion. These positives outweighed the negative free cash flow, elevated investment cycle, Other-segment losses, contract-manufacturing phase-outs and expected near-term margin pressure.

Company Guidance

Ypsomed raised its full-year guidance to top line growth of 13% to 16% on sales, from 12% to 15%, and EBIT of CHF 220 million to CHF 240 million, from CHF 210 million to CHF 230 million; fixed asset investments are expected to be close to CHF 300 million in business year '26/'27 before gradually going down, with the company expecting to be on free cash flow level positive in business year '27/'28. The midterm ambition remains sales of CHF 0.9 billion to CHF 1.1 billion and EBIT of CHF 280 million to CHF 340 million until business year '29/'30, with capital efficiency around 20% and a 15% CAGR; EBIT margin is expected to stay above 30%, although it may also mean we are way above 30%, while GLP-1 is expected to reach 1/3 by end of the decade from above 10% currently.

  • Raised Full-Year GuidanceYpsomed raised its full-year sales growth guidance from 12% to 15% to 13% to 16%, and increased its EBIT guidance from CHF 210 million to CHF 230 million to CHF 220 million to CHF 240 million.
  • Strong Delivery Systems GrowthDelivery Systems revenue grew 17.5% in the first half. Commercial sales increased from roughly CHF 200 million to CHF 243 million, representing more than 20% growth, driven mainly by the YpsoMate 1 ml and 2.25 ml autoinjector platforms.
  • Record Revenue and EBITYpsomed achieved CHF 318 million of total sales and CHF 102 million of EBIT in the first half, representing an EBIT margin of 35.7%, or close to 36%, similar to the prior business year.
  • Autoinjector Portfolio MomentumMore than 70% of revenue now comes from autoinjectors, with approximately one-third from pens. Autoinjectors grew faster than the 17.5% overall Delivery Systems rate, while the YpsoMate 1 ml and 2.25 ml platforms were identified as major growth drivers.
  • New Deals and CustomersYpsomed won 30 new deals or projects in the first six months, more than two-thirds of the number won during the entire prior year. It also added 10 new customers, bringing the total to 130 customers.
  • Broad Customer and Product PipelineThe company is active in close to 300 clinical and commercial programs, including approximately 280 programs discussed in the portfolio overview. Roughly 90 products are launched and approximately 190 are in development, with around 50 projects added to the portfolio each year. The 10 largest customers account for roughly 50% of business, while Novo is below 15%.
  • Strong Market PositionFour out of five device launches in developed markets over the past 12 months used an YpsoMate device. Ypsomed stated that its broad portfolio allows customers to switch between pens and autoinjectors and covers autoimmune diseases, incretins and diabetes, hormone therapies, rare diseases and other therapeutic areas.
  • GLP-1 and Incretin ExpansionYpsomed now has close to 50 GLP-1 or incretin clients and stated that GLP-1-related revenue is above 10% but well below one-third of revenue. Management previously indicated that the category could reach one-third by the end of the decade. The company has dedicated GLP-1 solutions including YpsoDot and YpsoFlow.
  • Growth in Larger-Volume DevicesThe 2.25 ml platform is growing above the 17.5% average Delivery Systems rate, and the company is moving into 5.5 ml devices. Ypsomed expects its first 5.5 ml product launch in Q1 2027 and stated that larger-volume products should have a positive midterm impact on the bottom line.
  • Innovation and Faster Time to MarketYpsomed is pre-verifying and pre-validating device, glass and rubber combinations and providing completed documentation to customers. This has reduced the time to market or clinic to below six months, with a target of three months, potentially allowing customers to use the same device from Phase IIb or III through commercialization.
  • Expected Benefits from YpsoFitThe YpsoFit program includes dual sourcing, new plastic suppliers and moving many customers from medical-grade to food-grade materials. Management expects the first effects in 2028, with the program softening the EBIT impact in 2028/2029 and contributing to an EBIT margin clearly above 30%.
  • AI and Manufacturing Productivity InitiativesThe company has invested in AI and aggregated manufacturing data to improve speed and precision, reduce waste, raise OEE and extend maintenance windows. Ypsomed stated that sensor data is being used to identify maintenance needs and that its vision is eventually to eliminate certain in-process controls as manufacturing stability improves.
  • Capacity Expansion Across RegionsYpsomed is expanding and automating capacity in Switzerland, Germany, China and the United States. The German site has space for 25,000 pallets and more than 0.5 billion autoinjectors and pens, with an initial capacity of roughly 250 million and room for another unit in 2029 or 2030. Holly Springs is expected to be handed over to manufacturing in September 2027, with the first product delivery targeted for Q1 2028.
  • China and Global Manufacturing FootprintThe Changzhou site has space for one additional production line and supplies China and neighboring markets. By approximately 2030 or 2031, Ypsomed expects China to represent roughly 120 million to 150 million of an approximately 1 billion-unit production capacity, while Germany is expected to account for about 50% of capacity.
  • Strong Cash Generation and Capital EfficiencyOperating cash flow was close to CHF 120 million, EBITDA for the last 12 months was above CHF 300 million, and first-half return on capital employed was around 20%. Management described the balance sheet as solid, with current debt of around CHF 300 million and net debt to EBITDA of approximately 1.0.
  • Long-Term Growth Ambition ConfirmedYpsomed confirmed its midterm ambition of CHF 0.9 billion to CHF 1.1 billion in sales and CHF 280 million to CHF 340 million in EBIT by business year 2029/2030, with capital efficiency expected to remain around 20%. Management also stated that growth is expected to remain sustained after 2030.
  • Broadening Therapeutic ApplicationsOf the 30 projects won during the first half, roughly 50%, or 16 to 17 projects, involve new molecules, including projects in new therapeutic areas such as neurology. Ypsomed also cited activity in autoimmune disease, oncology and infectious disease, and identified approximately five cases involving a move from intravenous to subcutaneous administration.

CH:YPSN Earnings History

CH:YPSN earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
May 26, 20272027 (Q4)8.64-6.11――
Nov 11, 20262027 (Q2)5.236.5010.19-36.21% (-3.69)
May 20, 20262026 (Q4)6.006.114.0251.88% (+2.09)
Nov 12, 20252026 (Q2)9.1110.192.39326.36% (+7.80)
May 21, 20252025 (Q4)―4.023.0631.26% (+0.96)
Nov 13, 20242025 (Q2)2.832.392.68-10.82% (-0.29)
May 22, 20242024 (Q4)―3.062.6316.58% (+0.44)
Nov 15, 20232024 (Q2)―2.681.17129.45% (+1.51)
May 24, 20232023 (Q4)―2.631.26108.49% (+1.37)
Nov 16, 20222023 (Q2)―1.170.56107.83% (+0.61)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed